Medicine & Life Sciences

1. Hodgkin Disease 100%
2. Non-Hodgkin's Lymphoma 98%
3. Waldenstrom Macroglobulinemia 96%
4. Lymphoma 80%
5. Lymphoma, Large B-Cell, Diffuse 79%
6. Follicular Lymphoma 61%
7. Survival 51%
8. B-Cell Lymphoma 49%
9. Rituximab 47%
10. Progression-Free Survival 44%
11. Brentuximab Vedotin 42%
12. B-Lymphocytes 35%
13. Stem Cell Transplantation 31%
14. T-Lymphocytes 30%
15. Therapeutics 29%
16. Neoplasms 29%
17. Drug Therapy 25%
18. Nivolumab 25%
19. T-Cell Lymphoma 22%
20. Tumor Microenvironment 21%
21. Transplants 21%
22. Anaplastic Large-Cell Lymphoma 21%
23. Lymphocyte Count 20%
24. Peripheral T-Cell Lymphoma 20%
25. Peripheral Blood Stem Cell Transplantation 19%
26. Lymphocytes 19%
27. Confidence Intervals 19%
28. Immunoglobulin M 18%
29. Hematopoietic Stem Cell Transplantation 18%
30. Multiple Myeloma 17%
31. PCI 32765 17%
32. Monocytes 17%
33. Hematologic Neoplasms 16%
34. Lymphoproliferative Disorders 15%
35. Mantle-Cell Lymphoma 15%
36. Cyclophosphamide 14%
37. Stem Cells 13%
38. Recurrence 13%
39. Autografts 13%
40. Immunotherapy 13%
41. Clinical Trials 13%
42. Bone Marrow 13%
43. B-Cell Chronic Lymphocytic Leukemia 13%
44. Lenalidomide 12%
45. Immunoglobulin Light-chain Amyloidosis 12%
46. Doxorubicin 12%
47. Cytokines 11%
48. Ligands 11%
49. Vincristine 10%
50. Single Nucleotide Polymorphism 10%